(Q37925813)

25 August 2017

1 reference

title

Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents (English)

1 reference

25 August 2017

main subject

anti-retroviral agent

0 references

author name string

Brian S Eley

series ordinal

1

1 reference

25 August 2017

Tammy Meyers

series ordinal

2

1 reference

25 August 2017

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

303-316

1 reference

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Antiretroviral treatment for children with peripartum nevirapine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Antiretroviral medication adherence and the development of class-specific antiretroviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Protease inhibitor resistance in South African children with virologic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pediatric HIV clinical care resources and management practices in Asia: a regional survey of the TREAT Asia pediatric network.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Provision of antiretroviral therapy to children within the public sector of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Sequencing of antiretroviral therapy in children in low- and middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Clinical use of CCR5 inhibitors in HIV and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593330-000000000-00000

Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.

21 January 2018

1 reference

12 December 2020

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children

1 reference

12 December 2020

Rifabutin for treating pulmonary tuberculosis

1 reference

12 December 2020

A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa

1 reference

12 December 2020

Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission

1 reference

12 December 2020

10.2165/11593330-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1025041465

0 references

1 reference